7 medtech stories we missed this week: Feb. 24, 2017

[Photo from unsplash.com]Several companies made distribution deals this week, while others received approval for their products. Here are 7 medtech stories we missed this week but were still worth mentioning. 1. Israel OKs E-Qure’s BST device for chronic wounds E-Qure Corp. announced this week that it received marketing approval for its Bio-electrical Signal Therapy Device (BST Device) from the Israeli Ministry of Health, according to a Feb. 24 news release. BST is an electrotherapeutic method for treating chronic wounds. E-Qure will begin marketing its device in Israel by activating a signed distribution agreement with Chemipal. The BST device is the first electrical device on the Israeli advanced wound care market. E-Qure will also start commercial activity in the private healthcare market and has already filed for BST treatment to be included in Israel’s approved National Health Basket. 2. Nexstim touts final results from Phase III trial Nexstim recently presented the results of a multi-center Phase III trial for the company’s Navigated Brain Therapy system (NBT) for stroke rehabilitation, according to a Feb. 23 news release. The results were presented at the International Stroke Conference in Houston, Texas by the lead investigator, Richard L. Harvey, M.D. The results showed that the NBT was safe and had no serious adverse events related to using the device. There was also significant clinical improvement of upper extremity motor function. Other results showed that...
Source: Mass Device - Category: Medical Equipment Authors: Tags: Electronic Medical Records Imaging Mergers & Acquisitions mHealth (Mobile Health) Regulatory/Clearance Align Technology Clarius Mobile Health Corin Group E-Qure Henry Schein Medical Nexstim Skyline Medical Source Type: news